Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2017-08-14
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597
administered subcutaneously during 52 weeks on lung function of participants with Idiopathic
Pulmonary Fibrosis (IPF).
Secondary Objectives:
To evaluate the efficacy of 2 dose levels/regimens of SAR156597 compared to placebo on IPF
disease progression.
To evaluate the safety of 2 dose levels/regimens of SAR156597 compared to placebo in
participants with IPF.